Litigation Details for Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2016)

Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2016)

Docket		Date Filed	2016-11-03
Court	Court of Appeals for the Federal Circuit	Date Terminated	2019-03-28
Cause		Assigned To
Jury Demand		Referred To
Patents	6,211,244; 6,723,340; 6,733,783; 7,674,799; 7,674,800; 7,683,072; 8,536,130
Link to Docket	External link to docket

Details for Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-11-03				External link to document

Grunenthal GmbH v. Alkem Laboratories Limited, 17-1153: Patent Litigation Summary and Analysis

Last updated: October 29, 2026

Grünenthal GmbH defeated Alkem Laboratories’ validity challenge to U.S. Patent No. 7,994,364, which covers extended-release tapentadol formulations marketed as Nucynta ER. The Federal Circuit affirmed the district court’s judgment that the asserted claims were not invalid for obviousness. The decision preserved Grünenthal’s Hatch-Waxman enforcement position against Alkem’s ANDA and delayed generic entry based on the patent at issue. Grünenthal GmbH v. Alkem Laboratories Ltd., 904 F.3d 1359 (Fed. Cir. 2018).

What patent did Grunenthal assert against Alkem Laboratories?

Grünenthal asserted U.S. Patent No. 7,994,364, generally directed to pharmaceutical formulations containing tapentadol in an extended-release dosage form.

Item	Details
Patent	U.S. Patent No. 7,994,364
Patent holder and plaintiff	Grünenthal GmbH
Defendant	Alkem Laboratories Limited
Product	Nucynta ER, extended-release tapentadol
Product type	Small-molecule opioid analgesic
Procedural vehicle	Hatch-Waxman patent litigation arising from an ANDA
Federal Circuit docket	No. 17-1153
Reported decision	904 F.3d 1359 (Fed. Cir. 2018)
Principal issue	Obviousness of the asserted extended-release tapentadol claims
Result	Federal Circuit affirmed the judgment for Grünenthal

The patent protected the extended-release delivery profile rather than tapentadol as a chemical compound generally. That distinction mattered because the active ingredient was known, while the dispute focused on whether the claimed extended-release formulation and resulting pharmacokinetic characteristics would have been obvious.

What was the Hatch-Waxman dispute in Grunenthal v. Alkem?

Alkem filed an abbreviated new drug application seeking FDA approval for a generic version of Nucynta ER. The ANDA filing created an artificial act of patent infringement under 35 U.S.C. § 271(e)(2), allowing Grünenthal to sue before commercial generic launch.

The litigation followed the standard Orange Book certification framework:

1. Grünenthal listed the ’364 patent for Nucynta ER.
2. Alkem submitted an ANDA containing a Paragraph IV certification challenging the patent.
3. Grünenthal filed an infringement action.
4. The litigation triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
5. The district court evaluated whether Alkem had shown that the asserted claims were invalid.
6. The Federal Circuit affirmed the ruling favorable to Grünenthal.

The case was therefore a patent-validity and generic-entry dispute, not a regulatory challenge to tapentadol’s safety or efficacy.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s determination that Alkem had not established obviousness.

The appellate court applied the conventional framework under 35 U.S.C. § 103:

• the scope and content of the prior art;
• the differences between the prior art and the asserted claims;
• the level of ordinary skill in the art; and
• objective indicia of nonobviousness.

The central question was whether a skilled artisan would have had a reason to select the claimed formulation parameters and a reasonable expectation of success in producing the claimed extended-release tapentadol product.

The Federal Circuit held that the district court did not clearly err in its underlying factual findings and did not err in its ultimate obviousness determination. The ruling preserved the patent’s enforceability against Alkem’s proposed generic product.

Why did Alkem lose its obviousness challenge?

The prior art did not provide a complete roadmap

Alkem relied on prior-art references concerning tapentadol, opioid formulations, sustained-release dosage forms, and pharmacokinetic characteristics. The Federal Circuit treated the prior art as requiring more than a general suggestion to make an extended-release product.

The existence of known sustained-release technologies did not, by itself, establish that the specific claimed formulation would have been obvious. The court focused on whether the prior art directed a skilled artisan toward the claimed combination with a reasonable expectation that it would achieve the required release and absorption characteristics.

Known active ingredient did not make the formulation automatically obvious

Tapentadol was known before the patent’s relevant filing date. That fact weakened the novelty of the active ingredient but did not eliminate the patentability inquiry for the dosage form.

The patent claims addressed the delivery system and pharmacokinetic performance of tapentadol. The Federal Circuit recognized that a known drug can support a valid formulation patent when the claimed release profile, dosage form, or administration characteristics are not adequately disclosed or suggested by the prior art.

Reasonable expectation of success was critical

The decision reflects a recurring pharmaceutical obviousness principle: an artisan’s ability to experiment is not the same as a reasonable expectation of success.

The court did not treat formulation development as a simple substitution exercise. Extended-release opioid products can be affected by drug solubility, matrix selection, dose loading, dissolution behavior, gastrointestinal transit, absorption, and food effects. The relevant legal question was whether the prior art made the claimed result predictable enough to satisfy § 103.

Objective indicia supported validity

The district court also considered secondary considerations, including commercial success and other evidence bearing on nonobviousness. These factors do not independently establish validity, but they can reinforce a conclusion reached from the prior-art analysis.

The Federal Circuit found no reversible error in the district court’s treatment of those considerations.

What was the litigation timeline?

Date or period	Event
2011	U.S. Patent No. 7,994,364 issued
Pre-2017	Grünenthal listed the patent for Nucynta ER in the FDA Orange Book
Before Federal Circuit appeal	Alkem filed an ANDA and made a Paragraph IV patent certification
District court phase	Grünenthal sued Alkem for ANDA-based patent infringement
2017	Federal Circuit appeal docketed as No. 17-1153
2018	Federal Circuit issued its decision in 904 F.3d 1359
After decision	The validity ruling remained favorable to Grünenthal, subject to the patent’s remaining term and any other litigation or regulatory developments

The reported appellate decision addressed patent validity. It did not establish a general market authorization date for Alkem’s product.

What was the Orange Book status of the Nucynta ER patent?

Nucynta ER is an FDA-approved extended-release tapentadol product. The ’364 patent was listed in connection with the product and used as the basis for Grünenthal’s Hatch-Waxman infringement action.

The Orange Book listing was commercially important because it required an ANDA applicant to address the listed patent through one of four certifications:

• Paragraph I: no patent information listed;
• Paragraph II: patent has expired;
• Paragraph III: applicant will wait until patent expiration; or
• Paragraph IV: patent is invalid, unenforceable, or will not be infringed.

Alkem’s Paragraph IV position created the litigation pathway. A successful Paragraph IV challenge could have enabled approval and launch before the listed patent’s expiration. Grünenthal’s successful defense prevented that result with respect to the challenged patent.

The reported patent expiration date for the ’364 patent was in 2025, subject to any applicable statutory extensions or listing-specific treatment. The Federal Circuit decision therefore protected the commercial position associated with the patent during the remaining term, rather than creating a new exclusivity period.

When did Nucynta ER lose patent exclusivity?

The ’364 patent was reported to expire on June 5, 2025. Any pediatric exclusivity, terminal disclaimer, regulatory exclusivity, or separate patent rights would need to be evaluated independently from the base patent term.

Patent expiration did not necessarily eliminate every barrier to generic entry on the same day. A generic applicant could still face:

• other Orange Book-listed patents;
• product-specific formulation patents;
• regulatory exclusivity;
• manufacturing or bioequivalence requirements;
• unresolved litigation;
• settlement restrictions; or
• commercial launch constraints.

The Grunenthal v. Alkem ruling concerned one patent and one ANDA dispute. It should not be read as a complete freedom-to-launch opinion for every generic tapentadol product.

What formulations were protected by the ’364 patent?

The relevant protection centered on extended-release tapentadol formulations and their performance characteristics. The patent estate was not limited to tapentadol’s molecular structure.

Formulation protection

The patent’s commercial relevance arose from claims directed to:

• tapentadol or a pharmaceutically acceptable salt;
• an extended-release dosage form;
• controlled drug release over time;
• pharmacokinetic properties associated with the formulation; and
• administration characteristics relevant to sustained analgesia.

These limitations gave Grünenthal a litigation position against generic products designed to provide an equivalent extended-release profile.

Method-of-use protection

The dispute was primarily formulation-focused. Method-of-use claims can create separate enforcement rights when they recite treatment of a defined patient population, pain condition, dosing regimen, or administration schedule. The reported Federal Circuit decision did not convert the ’364 patent into a broad method-of-use ruling covering every use of tapentadol.

Manufacturing protection

The case did not establish that the ’364 patent independently blocked every manufacturing route for tapentadol. Manufacturing patents, process patents, polymorph patents, and formulation patents should be analyzed separately. A generic manufacturer could avoid one formulation patent while remaining exposed to another patent directed to the active ingredient, process, dosage form, or method of treatment.

Did the case involve biosimilar risk?

No. Tapentadol is a small-molecule drug, and Alkem proceeded through the ANDA pathway rather than the biologics license application and biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution, not biosimilar substitution. The principal legal mechanisms were:

• Paragraph IV certification;
• ANDA-based infringement under § 271(e)(2);
• the 30-month FDA approval stay; and
• patent-term expiration.

Which company was challenging the Nucynta ER patent?

Alkem Laboratories was the ANDA challenger in the reported case. The company sought approval for a generic extended-release tapentadol product and challenged the ’364 patent’s validity.

The available appellate decision does not establish that Alkem was the only company pursuing a generic Nucynta ER product. Multiple ANDA applicants may separately challenge the same Orange Book patent, and one applicant’s loss does not automatically resolve the rights of unrelated applicants.

Was there a settlement agreement?

The reported Federal Circuit decision is a merits decision affirming Grünenthal’s favorable judgment. It does not disclose or establish a settlement agreement between Grünenthal and Alkem.

A later settlement, license, consent judgment, or confidential commercial arrangement could affect actual launch timing without changing the appellate holding. The reported case should therefore be characterized as an affirmed validity judgment, not as a disclosed settlement case.

What was the commercial significance of the ruling?

The ruling protected Grünenthal’s ability to enforce the ’364 patent against Alkem’s proposed extended-release tapentadol product.

The commercial effects were concentrated in four areas:

1. Generic launch timing. Alkem could not rely on its invalidity challenge to obtain an early launch.
2. Price erosion. Continued patent protection delayed the standard price reduction associated with generic substitution.
3. Revenue exposure. Nucynta ER revenue remained exposed to the patent’s remaining term and to any other approved generic or branded competitors.
4. Settlement leverage. A patent owner with an affirmed validity judgment generally has stronger negotiating leverage in later ANDA disputes involving the same product or related formulations.

The judgment did not guarantee continued market exclusivity after patent expiration. It also did not prevent competition from immediate-release tapentadol, other opioid analgesics, alternative pain therapies, or authorized generic strategies.

How strong was the Nucynta ER patent estate after the decision?

The ’364 patent was strengthened by the appellate ruling, but the overall patent estate should be assessed claim by claim.

Strength factor	Assessment
Appellate validity ruling	Strong for the specific obviousness issues decided
Claim scope	Concentrated on extended-release formulation and performance limitations
Chemical composition coverage	Not equivalent to broad compound protection
Orange Book leverage	Material while the patent remained listed and unexpired
Generic challenge risk	Reduced after the Federal Circuit decision, but not eliminated
Biosimilar risk	Not applicable
Post-expiration risk	High because formulation patent protection does not permanently prevent generic entry
Geographic coverage	U.S. decision only; no automatic effect in Europe, Canada, India, or other jurisdictions
Manufacturing barrier	Dependent on separate process and formulation patents

A Federal Circuit affirmance is particularly valuable in subsequent litigation because it limits the force of the same invalidity theory. It does not create issue preclusion for every different claim, product, prior-art reference, or defendant.

What generic launch scenarios existed after the decision?

Scenario 1: Launch after patent expiration

This was the lowest litigation-risk pathway for an ANDA applicant. The applicant could seek approval timed to the expiration of the ’364 patent and any applicable exclusivity period.

Scenario 2: At-risk launch after an unsuccessful Paragraph IV challenge

An applicant could theoretically launch at risk after adverse litigation, but that approach would expose it to damages, injunction, and further infringement proceedings. The affirmed judgment made this strategy less attractive for Alkem with respect to the adjudicated patent.

Scenario 3: Design-around formulation

A generic manufacturer could develop a formulation that avoided the asserted claim limitations. That strategy would require a separate infringement analysis and would still need to satisfy FDA bioequivalence requirements.

Scenario 4: Entry based on a different certification

If the patent expired or became delisted, a later applicant could rely on a Paragraph II or Paragraph III certification, depending on timing. That route would not require the same invalidity challenge.

What are the geographic limits of the decision?

The decision is binding on the parties within the U.S. federal patent system and carries Federal Circuit precedential value. It does not determine:

• validity of corresponding foreign patents;
• infringement under Indian, European, Canadian, or other national laws;
• regulatory approval outside the United States;
• market-entry rights in countries without an Orange Book system; or
• the status of separate U.S. patents.

International generic-launch analysis must be performed country by country. Patent term, claim construction, validity standards, regulatory exclusivity, and litigation procedures vary substantially by jurisdiction.

Key Takeaways

• Grünenthal prevailed against Alkem in Federal Circuit appeal No. 17-1153.
• The dispute concerned U.S. Patent No. 7,994,364 and extended-release tapentadol formulations.
• The Federal Circuit affirmed that the asserted claims were not invalid for obviousness.
• Alkem’s Paragraph IV challenge did not remove the patent barrier to generic Nucynta ER entry.
• The decision strengthened Grünenthal’s position for the ’364 patent during its remaining term.
• Tapentadol is a small molecule, so biosimilar analysis does not apply.
• The reported decision does not disclose a settlement agreement.
• The patent’s reported expiration was June 5, 2025, subject to applicable extensions and separate patent rights.
• The ruling was U.S.-specific and did not resolve foreign patent or regulatory rights.
• Generic entry after expiration could still depend on other patents, FDA requirements, and product-specific infringement analysis.

FAQs

What drug was at issue in Grunenthal GmbH v. Alkem Laboratories?

The case involved tapentadol, particularly the extended-release formulation marketed as Nucynta ER.

What patent number was litigated in the Alkem Nucynta ER case?

The principal patent was U.S. Patent No. 7,994,364.

Did the Federal Circuit invalidate the Nucynta ER patent?

No. The Federal Circuit affirmed the district court’s judgment that the asserted claims were not invalid for obviousness.

Was Alkem allowed to launch a generic Nucynta ER product immediately after the appeal?

The appellate decision did not authorize immediate launch. Any launch would have remained subject to the patent’s term, FDA approval status, other patents, and potential infringement exposure.

Is Grunenthal v. Alkem relevant to generic opioid formulation litigation?

Yes. The decision is relevant to obviousness analysis for pharmaceutical formulations, especially where the active ingredient is known but the claimed extended-release profile and formulation performance are not directly taught by the prior art.

References

1. Federal Circuit. (2018). Grünenthal GmbH v. Alkem Laboratories Ltd., 904 F.3d 1359 (Fed. Cir. 2018).

2. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Congress. (2012). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

4. U.S. Congress. (2012). Patent Act, 35 U.S.C. §§ 103, 271(e)(2).

5. United States Patent and Trademark Office. (2011). U.S. Patent No. 7,994,364: Pharmaceutical composition comprising tapentadol.